12 reports

The pivotal Phase ## LIBERTY ASTHMA QUEST study of dupilumab for the treatment of asthma completed enrollment during the third quarter of 2016.

  • Cholesterol
  • Pharmaceutical
  • United States
  • Company Financials
  • Regeneron Pharmaceuticals, Inc.
  • DYSLIPIDEMIA - PIPELINE BY KYORIN PHARMACEUTICAL CO LTD, H1 2017
  • DYSLIPIDEMIA - PIPELINE BY LIPICARD TECHNOLOGIES LTD, H1 2017

Its KETAS is a phosphodiesterase inhibitor agent for ameliorating bronchial asthma and cerebro-vascular disorders.

  • Cholesterol
  • Obesity
  • Pharmaceutical
  • Statins
  • Esperion Therapeutics, Inc.

" Atopic dermatitis represents a significant unmet medical need, with a health-related quality of life impact exceeding that of asthma, epilepsy and diabetes.

  • Antimalarials
  • Cholesterol
  • United States
  • Product Initiative
  • Vitae Pharmaceuticals, Inc.

About LIPO-## LIPO-## is an injectable formulation of salmeterol xinafoate, a well-known long-acting ß##-adrenergic receptor agonist used in several FDA-approved drugs, including ADVAIR for asthma.

  • Cholesterol
  • Obesity
  • World
  • Product Initiative
  • Neothetics, Inc.

R& D Progress Research and Development Brief PD-## Product Description VACCINE FOR ALLERGIC RHINITIS AND ASTHMA Product Description The vaccine candidate is under development for the development for the treatment of allergic rhinitis and asthma.

  • Cholesterol
  • Europe
  • World
  • Product Initiative
  • AFFiRiS AG

Sandoz Generic Advair Diskus®regulatory submission was accepted by FDA for treatment of asthma and airflow obstruction and reducing exacerbations in patients with COPD.

  • Cholesterol
  • Clinical Trial
  • Infectious Disease
  • United States
  • GlobalData's company

The trial evaluated the efficacy of three different doses of MN ## for the treatment of asthma.

  • Cholesterol
  • Digestive System Disorder
  • Pharmaceutical
  • United States
  • Product Initiative
  • DYSLIPIDEMIA - PIPELINE BY LIPICARD TECHNOLOGIES LTD, H2 2017
  • DYSLIPIDEMIA - PIPELINE BY REGENERON PHARMACEUTICALS INC, H2 2017

Its ketas product is a phosphodiesterase inhibitor agent for ameliorating bronchial asthma and cerebro-vascular disorders.

  • Cholesterol
  • Chronic Disease
  • United States
  • World
  • Product Initiative

The respiratory monitoring devices market is growing due to the rising incidence of chronic obstructive pulmonary diseases (COPD), asthma, and tuberculosis, coupled with technological advancements and growing awareness among people.

  • Cardiac Monitoring
  • Cholesterol
  • World
  • Market Size
  • Medtronic, Inc.

LICENSE OPTION IS FOR SYSTEMIC USES INCLUDING INFLAMMATORY BOWEL DISEASE AND SEVERE ASTHMA.

  • Cholesterol
  • Pharmaceutical
  • United States
  • Company
  • Product Initiative

ITS KETAS IS A PHOSPHODIESTERASE INHIBITOR AGENT FOR AMELIORATING BRONCHIAL ASTHMA AND CEREBRO-VASCULAR DISORDERS.

  • Cholesterol
  • Hospital
  • Pharmaceutical
  • United States
  • Product Initiative

The company' s KETAS is a phosphodiesterase inhibitor agent for ameliorating bronchial asthma and cerebro-vascular disorders.

  • Cholesterol
  • Pharmaceutical
  • United States
  • Product Initiative
  • Acasti Pharma Inc.